Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis
Open Access
- 18 October 2010
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 63 (3), 373-382
- https://doi.org/10.1002/acr.20372
Abstract
Objective To evaluate the long‐term safety and efficacy of etanercept therapy in rheumatoid arthritis (RA) patients. Methods Adult patients with early RA or longstanding RA received etanercept in open‐label extension studies following initial double‐blind trials of etanercept. Results Of 558 early RA patients and 714 longstanding RA patients who received at least 1 dose of etanercept, a total of 194 early RA patients and 217 longstanding RA patients were treated with 25 mg of etanercept twice weekly through 10 years. Five opportunistic infections were reported: in early RA, 1 Candida septicemia; in longstanding RA, 1 herpes zoster, 1 atypical mycobacterium infection, 1 meningoencephalitis (unspecified), and 1 fungal sepsis (unspecified). Twenty‐nine cases of sepsis occurred (10 early RA, 19 longstanding RA). Occurrence of all malignancies was similar to that expected in the general population, but the occurrence of lymphomas was higher than expected in the general population. Fourteen lymphomas (7 early RA, 7 longstanding RA) and 2 cases of demyelinating disease (1 early RA, 1 longstanding RA) were reported. Deaths occurred in 18 early RA patients and 43 longstanding RA patients. Both patient groups showed sustained improvement in American College of Rheumatology responses, swollen joint counts, Health Assessment Questionnaire disability index scores, and C‐reactive protein levels. Conclusion Etanercept maintained therapeutic benefits beyond 10 years of therapy in both early RA and longstanding RA patients, suggesting that etanercept is well tolerated and effective as a long‐term, continuous therapy for the treatment of RA, with a favorable risk/benefit ratio.Keywords
This publication has 16 references indexed in Scilit:
- Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics registerArthritis Care & Research, 2010
- A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugsAnnals Of The Rheumatic Diseases, 2006
- Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritisArthritis & Rheumatism, 2006
- Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonistsAnnals Of The Rheumatic Diseases, 2005
- Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor AntagonistsClinical Infectious Diseases, 2004
- Frequency of infection in patients with rheumatoid arthritis compared with controls: A population‐based studyArthritis & Rheumatism, 2002
- Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomesArthritis & Rheumatism, 2002
- Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty‐year periodArthritis & Rheumatism, 2002
- A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving MethotrexateNew England Journal of Medicine, 1999
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995